Alfredo Fonseca

KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int. Read the Guideline in KI: kdigo.co/KDIGO-IgAN-IgAV-Gui… Download the Executive Summary: kdigo.co/IgAN-IgAV-Guideline… Read the News Release: kdigo.co/KDIGO-IgAN-IgAV-Gui… Co-chaired by Dr. Jürgen Floege (DE) and @BradRovin, this update to the 2021 KDIGO Glomerular Diseases Guideline on IgAN incorporates evidence through August 2024. Given the rapid pace of discovery, KDIGO will continue to update the guideline regularly so clinicians and patients have access to the latest science and recommendations. “This guideline represents a fundamental shift in how we approach IgA nephropathy,” said Dr. Floege. “For the first time, we can target both the immune mechanisms driving IgA injury and the kidney’s maladaptive responses. This dual strategy offers a roadmap to slow progression and extend kidney survival in ways not possible just a few years ago.” “The science is moving faster than ever, and the treatment landscape has changed dramatically,” said Dr. Rovin. “With therapies like targeted-release budesonide, sparsentan, and SGLT2 inhibitors, we can intervene earlier and tailor care. We are moving from a single approach to a toolkit of therapies that can truly change outcomes for people around the world." Download the Guideline: kdigo.co/KDIGO-IgAN-IgAV-Gui…